Effects of pioglitazone and metformin on β-cell function in nondiabetic subjects at high risk for type 2 diabetes

被引:20
作者
Rasouli, Neda
Kern, Philip A.
Reece, E. Albert
Elbein, Steven C.
机构
[1] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Med, Div Endocrinol, Little Rock, AR USA
[3] Univ Arkansas Med Sci, Coll Med, Dept Obstet & Gynecol, Little Rock, AR USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2007年 / 292卷 / 01期
关键词
insulin sensitizer; prediabetes;
D O I
10.1152/ajpendo.00221.2006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 292:E359-E365, 2007. First published September 12, 2006;doi:10.1152/ajpendo.00221.2006. Thiazolidinediones (TZDs) and metformin decreased the incidence of diabetes in subjects at risk for developing diabetes and improved peripheral or hepatic insulin sensitivity, respectively. Whether they also directly improved beta-cell function is not clear. In vitro studies showed improved beta-cell function in response to TZDs and metformin; however, the effects of TZDs or metformin on beta-cell function in humans are still uncertain. We hypothesized that both TZDs and metformin directly affect beta-cell function. We evaluated beta-cell function and insulin sensitivity (SI) in subjects with impaired glucose tolerance or a history of gestational diabetes using oral and intravenous glucose tolerance tests in addition to the glucose-potentiated arginine stimulation test. In contrast to metformin, pioglitazone improved S-I, glucose tolerance, and insulin-independent glucose disposal [glucose effectiveness (SG)]. Neither pioglitazone nor metformin significantly improved beta-cell compensation for insulin resistance [disposition index (DI)], but the change in DI significantly correlated with baseline SI. Insulin secretion in response to arginine at maximally potentiating glucose levels (AIR(max)) tended to increase after metformin and to decrease after pioglitazone; however, when adjusted for SI, the changes were not significant. Our results demonstrate that, in nondiabetic subjects at risk for diabetes, pioglitazone, but not metformin, significantly improved glucose tolerance by improving SI and SG. We did not find any evidence that either pioglitazone or metformin improved beta-cell function. Improved beta-cell compensation was observed primarily in the subgroup of subjects that had the lowest SI at baseline.
引用
收藏
页码:E359 / E365
页数:7
相关论文
共 37 条
[1]   QUANTITATIVE ESTIMATION OF INSULIN SENSITIVITY [J].
BERGMAN, RN ;
IDER, YZ ;
BOWDEN, CR ;
COBELLI, C .
AMERICAN JOURNAL OF PHYSIOLOGY, 1979, 236 (06) :E667-E677
[2]   EQUIVALENCE OF THE INSULIN SENSITIVITY INDEX IN MAN DERIVED BY THE MINIMAL MODEL METHOD AND THE EUGLYCEMIC GLUCOSE CLAMP [J].
BERGMAN, RN ;
PRAGER, R ;
VOLUND, A ;
OLEFSKY, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (03) :790-800
[3]  
Boston Ray C, 2003, Diabetes Technol Ther, V5, P1003, DOI 10.1089/152091503322641060
[4]   Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].
Buchanan, TA ;
Xiang, AH ;
Peters, RK ;
Kjos, SL ;
Marroquin, A ;
Goico, J ;
Ochoa, C ;
Tan, S ;
Berkowitz, K ;
Hodis, HN ;
Azen, SP .
DIABETES, 2002, 51 (09) :2796-2803
[5]   Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes [J].
Buchanan, TA ;
Xiang, AH ;
Peters, RK ;
Kjos, SL ;
Berkowitz, K ;
Marroquin, A ;
Goico, J ;
Ochoa, C ;
Azen, SP .
DIABETES, 2000, 49 (05) :782-788
[6]   Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance [J].
Cavaghan, MK ;
Ehrmann, DA ;
Byrne, MM ;
Polonsky, KS .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (03) :530-537
[7]  
Diabetes Prevention Progam, 2005, DIABETES, V54, P1150
[8]   Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome [J].
Ehrmann, DA ;
Schneider, DJ ;
Sobel, BE ;
Cavaghan, MK ;
Imperial, J ;
Rosenfield, RL ;
Polonsky, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2108-2116
[9]   The evolving diabetes burden in the United States [J].
Engelgau, MM ;
Geiss, LS ;
Saaddine, JB ;
Boyle, JP ;
Benjamin, SM ;
Gregg, EW ;
Tierney, EF ;
Rios-Burrows, N ;
Mokdad, AH ;
Ford, ES ;
Imperatore, G ;
Narayan, KMV .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (11) :945-950
[10]   Beta cell function and its relation to insulin action in humans: a critical appraisal [J].
Ferrannini, E ;
Mari, A .
DIABETOLOGIA, 2004, 47 (05) :943-956